In This Issue
ACR Announcements
Issue Information
Clinical Connections
Review : Immune‐Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer
Rheumatoid Arthritis and Risk of Malignant Lymphoma : Is the Risk Still Increased?
Peficitinib, a JAK Inhibitor, in the Treatment of Moderate‐to‐Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate
Different Rating of Global Rheumatoid Arthritis Disease Activity in Rheumatoid Arthritis Patients With Multiple Morbidities
Brief Report : Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis
Brief Report : The Role of Rare Protein‐Coding Variants in Anti–Tumor Necrosis Factor Treatment Response in Rheumatoid Arthritis
Phenome‐Wide Association Study of Autoantibodies to Citrullinated and Noncitrullinated Epitopes in Rheumatoid Arthritis
The Transcriptional Coactivator Bob1 Is Associated With Pathologic B Cell Responses in Autoimmune Tissue Inflammation
Long‐Term Safety and Efficacy of Fulranumab in Patients With Moderate‐to‐Severe Osteoarthritis Pain : A Phase II Randomized, Double‐Blind, Placebo‐Controlled Extension Study
Discovery of T Cell Receptor β Motifs Specific to HLA–B27–Positive Ankylosing Spondylitis by Deep Repertoire Sequence Analysis
Brief Report : Longitudinal Patterns of Response to Standard of Care Therapy for Systemic Lupus Erythematosus
Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus : A Multicenter, Double‐Blind, Randomized, Parallel‐Group Trial
Expression of Cyclic GMP‐AMP Synthase in Patients With Systemic Lupus Erythematosus
Brief Report : CD4+ T Cells From Patients With Systemic Lupus Erythematosus Respond Poorly to Exogenous Interleukin‐2
VISTA Deficiency Accelerates the Development of Fatal Murine Lupus Nephritis
Ultraviolet B Irradiation Causes Stimulator of Interferon Genes–Dependent Production of Protective Type I Interferon in Mouse Skin by Recruited Inflammatory Monocytes
Clinical Images : Hematoidin in Synovial Fluid
A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Giant Cell Arteritis
A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Takayasu Arteritis
Anakinra for Colchicine‐Resistant Familial Mediterranean Fever : A Randomized, Double‐Blind, Placebo‐Controlled Trial
Middle Initial Omitted From Author Name in the Article by Felson et al (Arthritis Rheumatol, February 2017)
Reanalysis of the Multi‐Biomarker Disease Activity Score for Assessing Disease Activity in the Abatacept Versus Adalimumab Comparison in Biologic‐Naive Rheumatoid Arthritis Subjects with Background Methotrexate Study : Comment on the Article by Fleischmann et al
Limited Value of the Multi‐Biomarker Disease Activity Assay Compared to the Routine Assessment of Patient Index Data 3 (RAPID3) Score in the Prognosis of Important Clinical Outcomes in Rheumatoid Arthritis : Comment on the Article by Fleischmann et al and Accompanying Editorial by Davis
Reply
The Role of Omalizumab in Patients With Eosinophilic Granulomatosis With Polyangiitis (Churg‐Strauss) : Comment on the Article by Jachiet et al
Biologic Therapy for Eosinophilic Granulomatosis With Polyangiitis (Churg‐Strauss) : Comment on the Article by Jachiet et al
Reply